^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ANLN (Anillin Actin Binding Protein)

    i
    Other names: ANLN, Anillin Actin Binding Protein, Anillin, Scraps, Scra, Anillin, Actin Binding Protein (Scraps Homolog, Drosophila), Anillin (Drosophila Scraps Homolog), Actin Binding Protein, ANILLIN, FSGS8
    Associations

    News

    Trials
    24d
    Over-expression of Anillin Actin Binding Protein in Adrenocortical Carcinoma Tissues Is Associated With Poorer Prognosis of Patients. (PubMed, Anticancer Res)
    ANLN may be a prognostic biomarker for patients with ACC and may play a role in tumor biology. Further studies are needed to determine whether ANLN is clinically useful as a prognostic factor in the treatment of ACC and to clarify its involvement in the mechanism of malignant progression of ACC.
    Journal
    |
    ANLN (Anillin Actin Binding Protein)
    27d
    Alterations in the transcriptional profile of genes in tumors as a prerequisite for personalization of treatment in breast cancer patients (PubMed, Arkh Patol)
    Comparative mRNA expression analysis confirms that a short preoperative course of aromatase inhibitors induces a more potent and uniform molecular response, characterized by profound suppression of proliferation and complete inhibition of estrogen-dependent signaling. Tamoxifen therapy is also effective but results in less pronounced suppression of key targets and, crucially, may be accompanied by early activation of the MYC oncogene, a potential marker for resistance development.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • FGFR4 (Fibroblast growth factor receptor 4) • BIRC5 (Baculoviral IAP repeat containing 5) • TYMS (Thymidylate Synthetase) • AURKA (Aurora kinase A) • FOXA1 (Forkhead Box A1) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • BAG1 (BAG Cochaperone 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting) • GATA3 (GATA binding protein 3) • KRT5 (Keratin 5) • MMP11 (Matrix Metallopeptidase 11) • MYBL2 (MYB Proto-Oncogene Like 2) • SFRP1 (Secreted frizzled related protein 1) • TMEM45B (Transmembrane Protein 45B) • ANLN (Anillin Actin Binding Protein) • CCNB1 (Cyclin B1) • SCGB2A2 (Secretoglobin Family 2A Member 2) • ZNF703 (Zinc Finger Protein 703)
    |
    HER-2 negative • HER-2 expression
    |
    tamoxifen • letrozole • anastrozole
    1m
    The role of ANLN in malignant tumors: pathogenesis, treatment resistance and targeted strategies. (PubMed, Front Cell Dev Biol)
    Recent studies have demonstrated that ANLN contributes to resistance to chemotherapy, targeted therapy, and immunotherapy through multiple molecular mechanisms. This review provides a systematic overview of the physiological functions of ANLN, its roles in cancer initiation and progression, and its regulatory mechanisms in treatment resistance, offering biological insights into precision oncology and potential strategies for overcoming therapeutic resistance in cancer.
    Review • Journal • IO biomarker
    |
    RHOA (Ras homolog family member A) • ANLN (Anillin Actin Binding Protein)
    1m
    VIRMA/IGF2BP3-mediated ANLN upregulation promotes intrahepatic cholangiocarcinoma growth by forming a positive feedback loop with RhoA/YAP1/TEAD1 signaling pathway. (PubMed, Cell Death Dis)
    Importantly, two clinical drugs, the RhoA inhibitor simvastatin and the YAP1/TEAD inhibitor verteporfin were determined to be the disruptors of this feed-forward signaling axis, inhibiting ICC tumor growth. These findings reveal the vital function of ANLN in ICC growth and provide promising treatment strategies for ICC.
    Journal
    |
    YAP1 (Yes associated protein 1) • RHOA (Ras homolog family member A) • ANLN (Anillin Actin Binding Protein) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) • TEAD1 (TEA Domain Transcription Factor 1) • VIRMA (Vir Like M6A Methyltransferase Associated)
    |
    Visudyne (verteporfin) • simvastatin
    2ms
    Network-based insights into miR-30a-5p-mediated regulation and EGCG targeting in triple-negative breast cancer. (PubMed, Front Bioinform)
    The results emphasizes that EGCG has strong binding affinity towards YWHAZ, revealing that miR-30a-EGCG targets TNBC synergistically through cell-cycle-mediated pathways. The findings give rational support for miRNA-guided phytochemical-based TNBC therapeutic development.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • PCNA (Proliferating cell nuclear antigen) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • CDC20 (Cell Division Cycle 20) • KIF11 (Kinesin Family Member 11) • ANLN (Anillin Actin Binding Protein) • CCNA1 (Cyclin A1) • MIR30A (MicroRNA 30a) • SKP2 (S-phase kinase-associated protein 2) • YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta)
    |
    HER-2 expression
    2ms
    Oncogenic Function of miR-182-5p Versus Tumor-Suppressive Activities of miR-203, miR-150-5p, and miR-139-5p via Target Gene Regulation in Colon Cancer Metastasis. (PubMed, Iran J Pharm Res)
    Mechanistically, miR-182-5p enhanced metastasis via ANLN and PDE4D regulation, whereas miR-203, miR-150-5p, and miR-139-5p suppressed metastasis through PDE4D, NEGR1, and ATP11A pathways, respectively. These results highlight the opposing roles of miR-182-5p and the tumor-suppressive miRNAs in CRC metastasis and suggest their potential as biomarkers and therapeutic targets.
    Journal
    |
    MIR139 (MicroRNA 139) • MIR182 (MicroRNA 182) • ANLN (Anillin Actin Binding Protein) • MIR150 (MicroRNA 150) • MIR203A (MicroRNA 203a)
    2ms
    Integrated Multiomics Unravels Hedgehog (HH) Signaling Characteristics in Pancreatic Cancer (PC) and DCBLD2 Regulates HH Signaling to Drive PC Progression. (PubMed, Hum Mutat)
    Consensus clustering was utilized to classify PC samples into two HH signaling-related subtypes: HRGcluster A and HRGcluster B. In contrast with HRGcluster A, HRGcluster B has an earlier clinical stage, better outcome, less active level of HH signaling, higher infiltration level of CD8+ T cells and B cells, and a greater likelihood of benefiting from immunotherapy and gemcitabine chemotherapy...In vitro assays further indicated that DCBLD2 knockdown downregulates HH signaling and inhibits the proliferation, migration, and invasion of PC cells. In conclusion, this study reveals that HH signaling characteristics in PC and DCBLD2 regulate HH signaling to drive PC progression, providing new perspectives and theories for the diagnosis and treatment of PC.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • SERPINB3 (Serpin family B member 3) • ANLN (Anillin Actin Binding Protein)
    |
    gemcitabine
    2ms
    Uncovering functional divergence and cellular clusters with specific gene signatures in HNSCC clonal spheroids. (PubMed, Cell Commun Signal)
    Hyperproliferative spheroids (HRPS) showed increased proliferation and tumorigenic potential, whereas hypoproliferative spheroids (HOPS) demonstrated enhanced migration and resistance to cisplatin and radiation...Notably, the gene expression profiles of Cluster 3 in the HOPS and Cluster 1 in the HRPS closely matched the expression patterns observed in the HNSCC-TCGA dataset. These clusters also displayed a high transcriptional correlation between patient tumors and their xenografts, reinforcing the clonal nature of HNSCC's genetic and functional diversity of HNSCC.
    Journal • Gene Signature
    |
    TOP2A (DNA topoisomerase 2-alpha) • AURKA (Aurora kinase A) • ALDH3A1 (Aldehyde Dehydrogenase 3 Family Member A1) • ANLN (Anillin Actin Binding Protein) • CKS2 (CDC28 Protein Kinase Regulatory Subunit 2)
    |
    cisplatin
    3ms
    PANoptosis-related gene clusters and prognostic risk model in clear cell renal cell carcinoma. (PubMed, Front Genet)
    Additionally, the PRG risk score model exhibited significant associations with sensitivity to multiple drugs. This novel PANoptosis-based model addresses the knowledge gap by providing enhanced prognostic accuracy and clinical utility for personalized ccRCC management, potentially guiding targeted and immunotherapeutic strategies.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • WDR72 (WD Repeat Domain 72) • ANLN (Anillin Actin Binding Protein) • SLC16A12 (Solute Carrier Family 16 Member 12)
    3ms
    A novel risk model incorporating 4 mitochondrial unfolded protein response-related genes to predict the prognosis, gene mutation landscape, and immunotherapy response in lung adenocarcinoma. (PubMed, Eur J Med Res)
    The 4 MRGs may contribute to the understanding on UPRmt in LUAD and the development of relevant medicine in clinical practice.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CREBBP (CREB binding protein) • KDM6B (Lysine Demethylase 6B) • ANLN (Anillin Actin Binding Protein) • KRT6A (Keratin 6A) • LRPPRC (Leucine Rich Pentatricopeptide Repeat Containing)
    |
    sirolimus • PHA665752 • seliciclib (CYC202)